Maraganore John's Form 4 filing
Alnylam Pharmaceuticals, Inc. (ALNY) · filed Aug 16, 2021
- Accession no.
- 0001735276-21-000083
- Filed
- Aug 16, 2021
- Trade date
- Aug 13, 2021
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 6 non-derivative transactions and 1 derivative transaction. Open-market sales total $6.79M. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Maraganore JohnCIK 0001180432 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 13, 2021 | Common Stock | MOption exerciseAcquired | +33,979 | $7.10 | +$241,250.9 | 248,744 | Direct | |
| Aug 13, 2021 | Common Stock | SSaleDisposed | −2,441 | $198.02F2 | −$483,366.82 | 246,303 | Direct | |
| Aug 13, 2021 | Common Stock | SSaleDisposed | −4,160 | $198.93F3 | −$827,548.8 | 242,143 | Direct | |
| Aug 13, 2021 | Common Stock | SSaleDisposed | −23,336 | $199.92F4 | −$4,665,333.12 | 218,807 | Direct | |
| Aug 13, 2021 | Common Stock | SSaleDisposed | −3,828 | $200.84F5 | −$768,815.52 | 214,979 | Direct | |
| Aug 13, 2021 | Common Stock | SSaleDisposed | −214 | $201.55 | −$43,131.7 | 214,765 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 13, 2021 | Common Stock | MOption exerciseDisposed | −33,979 | $0.00 | $0 | 33,978 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Sale prices ranged from $197.44 to $198.44.
Referenced by the price of 1 transaction in Table I.
- F3
Sale prices ranged from $198.45 to $199.44.
Referenced by the price of 1 transaction in Table I.
- F4
Sale prices ranged from $199.46 to $200.45.
Referenced by the price of 1 transaction in Table I.
- F5
Sale prices ranged from $200.48 to $201.43.
Referenced by the price of 1 transaction in Table I.